Bioimpedance spectroscopy (BIS) technology

Bioimpedance spectroscopy (BIS) is the only noninvasive, low-cost technology that can accurately measure a patient’s total body water, extracellular and intracellular fluid volumes in a clinical setting. This detailed data can help healthcare professionals with early detection, assessment and interventions for chronic conditions.

BIS detects medically meaningful fluid shifts as low as 36 ml in a limb.1

95% reduction in lymphedema progression using BIS for early detection combined with at-home intervention.2

A combination of BIS measurements offers the best option to manage heart failure.3

More about BIS

BIS is the most advanced method of using bioimpedance measurements to assess fluid levels and tissue composition. Bioimpedance measurements are taken by sending a painless electrical current through the body and measuring the body’s resistance and reactance to this electrical current. ImpediMed’s BIS technology uses these signals to quickly and non-invasively assess fluid and tissue status of patients for the purpose of managing chronic disease.

Clinically proven

ImpediMed and our subsidiaries pioneered the use of BIS technology, producing the first commercially available BIS devices in 1990. Our patented, clinically proven BIS technology measures impedance at 256 different frequencies, from 3 kHz to 1000 kHz, and uses validated mathematical models to determine three pure resistance values in the body:

  • Resistance at zero frequency, which translates to the free fluid outside of the body’s cells
  • Intracellular resistance, which translates to the intracellular fluid inside the body’s cells
  • Resistance at infinite frequency, which translates to the total body water including fluid inside of the body’s cells

These values form the foundation of all of the tissue and fluid output measures produced by ImpediMed’s BIS products.

Limitations of other systems

In contrast, other bioimpedance systems use multi-frequency bioimpedance analysis (MF-BIA). Unlike BIS, MF-BIA devices typically measure impedance at 2-6 different frequencies and are unable to determine the pure resistance values at zero and infinite frequencies. MF-BIA relies instead on equations applied to single-frequency impedances to create readings of the patient’s fluid levels. None of these provides a pure quantification of the different fluid compartments in the body.

BIS technology

Extensively researched

ImpediMed’s BIS technology has been studied in more than 500 peer-reviewed, published articles and over 40 different disease states or medical conditions. These studies have demonstrated the utility of BIS in monitoring fluid status and tissue composition for multiple purposes including the management of chronic diseases.

SOZO®

SOZO, the world’s most advanced, noninvasive BIS device, incorporates L-Dex® technology to aid in the assessment of secondary lymphedema and delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds.

Clinical evidence

ImpediMed’s BIS technology has been extensively studied in over 40 medical conditions and disease states.

References

  1. Ward L. Is BIS ready for prime time as the gold standard measure? Journal of Lymphoedema, 2009. 4(2): p. 52-56.
  2. Ridner SH, et al. A randomized trial evaluating bioimpedance spectroscopy versus tape measurement for the prevention of lymphedema following treatment for breast cancer: interim analysis. Ann Surg Oncol 2019; https://doi.org/10.1245/s10434-019-07344-5
  3. Weyer S, et al. Bioelectrical impedance spectroscopy as a fluid management system in heart failure. Physiol Meas, 2014. 35(6): p. 917-30.